The Ventricular Assist Devices (VAD) Market worldwide reached 2.24 billion dollars in 2022 and is projected to experience a rapid revenue compound annual growth rate (CAGR) of 12% during the forecast period. The increasing prevalence of heart failure and the growing global geriatric population affected by chronic diseases such as diabetes, neurological disorders, Cardiovascular Diseases (CVDs), hypertension, and stroke are key factors contributing to the growth of market revenue. VADs are mechanical circulatory support devices that assist in pumping blood from the lower chambers of the heart to the rest of the body. Heart failure affects approximately 26 million individuals globally, and its incidence is rapidly increasing. VADs offer a viable alternative to heart transplantation for individuals with end-stage heart failure.
Furthermore, the development of VAD technology is driving the growth of the market. Substantial advancements in VAD technology in recent years have improved device efficacy, durability, and design. For instance, the introduction of continuous-flow VADs has led to better patient outcomes and fewer complications compared to conventional pulsatile VADs.
Get a free sample PDF of the report, visit @
https://www.reportsanddata.com/download-free-sample/6166
The rising popularity of minimally invasive surgical techniques for VAD implantation is also contributing to market revenue growth. Surgeons can now implant VADs with minimal or no incisions using minimally invasive surgical methods, which reduce recovery times and complications.
The demand for VADs is expected to increase as the population ages and becomes more susceptible to heart failure. Additionally, increased awareness of VADs and their benefits among patients and healthcare professionals is anticipated to drive market revenue growth during the forecast period.
However, complications associated with VADs, such as bleeding, ischemic and hemorrhagic stroke, thrombosis, infections, and multi-organ failure, may restrain market revenue growth.
Product-wise, the global VAD market is segmented into Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), and Bi-Ventricular Assist Device (Bi-VAD). In 2022, the LVAD segment accounted for the largest share of revenue in the global VAD market. This can be attributed to the increasing rates of heart disease and the aging population. The LVAD is a mechanical implant that assists the heart in pumping blood when the left ventricle is unable to do so efficiently. The segment's revenue growth is also driven by the increasing number of cardiac transplants and the limited availability of donor organs.
The RVAD segment is expected to experience significant revenue growth in the global VAD market during the forecast period. This can be attributed to the rising rates of congenital cardiac disorders and right-sided heart failure, particularly in patients with left-sided heart failure. When the right ventricle is unable to pump blood properly, an RVAD is inserted into the ventricle to provide mechanical support.
The Bi-VAD segment is expected to hold a considerable revenue share in the global VAD market during the forecast period. The prevalence of biventricular heart failure, which occurs when both the left and right ventricles are unable to pump blood properly, is increasing. Bi-VAD is a mechanical device implanted into both ventricles to assist the heart in effectively pumping blood.
In terms of flow type, the global VAD market is segmented into pulsatile flow and continuous flow. In 2022, the continuous flow segment accounted for the largest share of revenue in the global VAD market. Continuous flow VADs have compact size, increased durability, and reduced power consumption. They are inserted into the chest and attached to the aorta and left ventricle to support blood circulation. These VADs require a smaller pump, making the implantation process more comfortable for patients. Additionally, continuous flow VADs have demonstrated a decreased likelihood of device failure and blood clotting, leading to improved patient outcomes.
The pulsatile flow VADs segment is expected to experience significant revenue growth in the global VAD market during the forecast period. Pulsatile flow VADs are increasingly used to produce pulsing blood flow, which simulates the natural rhythm of the heart. Despite being larger in size and having a higher chance of device failure, pulsatile flow VADs help improve patients' quality of life by providing a more natural blood flow.
In terms of regional analysis, the North America market accounted for the largest share of revenue in the global VAD market in 2022. This can be attributed to the rising prevalence of heart failure and the aging population in the region. Additionally, the implementation of advanced technologies and increased awareness among patients and healthcare professionals about VADs are expected to drive market revenue growth in North America.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/6166
The Asia Pacific market is expected to register the fastest revenue growth rate in the global VAD market during the forecast period. This can be attributed to the increasing incidence of heart failure and the aging population in countries like Japan, China, and India. The availability of advanced healthcare infrastructure and the implementation of cutting-edge technology in the healthcare industry are also expected to contribute to market revenue growth in the Asia Pacific region.
The European market is expected to hold a considerable revenue share in the global VAD market during the forecast period. This can be attributed to the rising prevalence of heart failure, the aging population, and the presence of advanced healthcare infrastructure in the region. Additionally, increasing research and development efforts related to VADs are driving market revenue growth in Europe.
The global VAD market is highly competitive, with several major players accounting for a significant market share. Companies in the market are focused on developing more effective products, entering into strategic agreements, and engaging in mergers and acquisitions. Some of the major companies operating in the global VAD market include:
- Abbott Laboratories
- Bivacor Inc.
- Boston Scientific Corporation
- Fresenius Medical Care AG Co. KGaA
- Medtronic
- St. Jude Medical, Inc.
- SynCardia Systems, LLC.
- Terumo Corporation
- Thoratec Corporation
- Abiomed, Inc.
In terms of strategic developments, on January 21, 2021, Boston Scientific Corporation acquired Preventice Solutions, a company specializing in remote patient monitoring and wearables technology. This acquisition aimed to expand Boston Scientific's digital health offerings and provide better support for patients using ventricular assist devices. On May 20, 2021, Bivacor Inc. announced the completion of its preclinical study for its fully implantable artificial heart, which is expected to be the first of its kind to receive FDA approval. On January 24, 2019, Medtronic announced its acquisition of EPIX Therapeutics, a company specializing in cardiac ablation technology, to expand its portfolio of heart failure treatments, including ventricular assist devices.
In terms of new product launches, on June 8, 2021, Abbott Laboratories launched its HeartMate 3 Left Ventricular Assist Device (LVAD) for patients with advanced heart failure. This fully implanted device helps the heart pump blood and features advanced sensing technology to monitor heart function and adjust device settings accordingly.
In conclusion, the global Ventricular Assist Devices (VAD) market is experiencing significant growth, driven by factors such as the rising prevalence of heart failure, advancements in VAD technology, the popularity of minimally invasive surgical techniques, and increasing awareness among patients and healthcare professionals. The market is segmented based on product type (LVAD, RVAD, Bi-VAD), flow type (pulsatile flow, continuous flow), and region (North America, Europe, Asia Pacific). The market is highly competitive, with major players focusing on product development and strategic partnerships. With the aging population and increasing susceptibility to heart failure, the demand for VADs is expected to continue to rise in the coming years.
Request a customized copy of the report @
https://www.reportsanddata.com/request-customization-form/6166
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports…
Osteomyelitis Treatment Market
Bronchiectasis Treatment Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
